SavedAdd your journal

Journals / Online Türk Sağlık Bilimleri Dergisi / 2021 / Cilt: 6 Sayı: 4

Agomelatine Reverses Scopolamine-Induced Learning and Memory Impairment in Adult Rats

Agomelatin Yetişkin Sıçanlarda Skopolamin Kaynaklı Öğrenme ve Hafıza Bozukluğunu Tersine Çevirir

Sinan Saral(RECEP TAYYIP ERDOGAN UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-0961-1903
Atilla Topçu(RECEP TAYYİP ERDOGAN UNİVERSİTESİ TIP FAKÜLTESİ)0000-0003-4730-5015
Ayşegül Sümer(RECEP TAYYIP ERDOGAN UNIVERSITY, SCHOOL OF MEDICINE)0000-0003-4918-4368
Ali Koray Kaya(RECEP TAYYIP ERDOGAN UNIVERSITY, SCHOOL OF MEDICINE)0000-0003-2433-5115
Aykut Öztürk(RECEP TAYYIP ERDOGAN UNIVERSITY, SCHOOL OF MEDICINE)0000-0003-4515-6968
Esra Pınarbaş(RECEP TAYYIP ERDOGAN UNIVERSITY, SCHOOL OF MEDICINE)0000-0001-6231-7597
Pages
535–541
Publication Date
2021-12-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, the potential effects of agomelatine in rats with scopolamine-induced cognitive impairment were investigated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The antidepressant agomelatine agent is a melatonin receptor (MT1 and MT2) agonist and a serotonin receptor (5-HT2C) antagonist.
📊
Key Findings & Data:Increasing evidence shows that agomelatine has neuroprotective and neuromodulatory effects.
💡
Conclusion & Impact:In this study, the potential effects of agomelatine in rats with scopolamine-induced cognitive impairment were investigated.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Agomelatin · asetilkolin · BDNF

Abstract

Objective: The antidepressant agomelatine agent is a melatonin receptor (MT1 and MT2) agonist and a serotonin receptor (5-HT2C) antagonist. Increasing evidence shows that agomelatine has neuroprotective and neuromodulatory effects. In this study, the potential effects of agomelatine in rats with scopolamine-induced cognitive impairment were investigated.

Özet

Amaç: Agomelatin, melatonin reseptör (MT1 ve MT2) agonisti ve serotonin reseptör (5-HT2C) antagonisti olan antidepresan bir ilaçtır. Artan kanıtlar, agomelatinin nöroprotektif ve nöromodülatör etkiye sahip olduğunu göstermektedir. Bu çalışmada skopolamin indüklü bilişsel yetmezlik oluşturulan sıçanlarda agomelatinin potansiyel etkileri araştırılmıştır.

🔖

Cite This Article

Saral, S., Topçu, A., Sümer, A., Kaya, A. K., Öztürk, A., Pınarbaş, E., *, S. S. (2021). Agomelatine Reverses Scopolamine-Induced Learning and Memory Impairment in Adult Rats. Online Türk Sağlık Bilimleri Dergisi, Cilt: 6 Sayı: 4, 535–541. https://doi.org/10.26453/otjhs.975452

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (29)

  1. Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer ’ s disease. 2019;5:1-18.
  2. Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev. 2016;67:89-101. doi:10.1016/j.neubiorev.2016.04.012
  3. Dos Santos TC, Gomes TM, Pinto BAS, Camara AL, De Andrade Paes AM. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer’s disease therapy. Front Pharmacol. 2018;9(OCT):1-14. doi:10.3389/fphar.2018.01192
  4. Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. Neurosci Biobehav Rev. 2011;35(6):1397-1409. doi:10.1016/j.neubiorev.2011.03.001
  5. Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev. 2010;34(8):1307-1350. doi:10.1016/j.neubiorev.2010.04.001
  6. Haider S, Tabassum S, Perveen T. Scopolamine-induced greater alterations in neurochemical profile and increased oxidative stress demonstrated a better model of dementia: A comparative study. Brain Res Bull. 2016;127:234-247. doi:10.1016/j.brainresbull.2016.10.002
  7. Tota SK, Hanif K, Kamat PK, Najmi AK, Nath C. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology (Berl). 2012;222(2):185-202. doi:10.1007/s00213-012-2639-7
  8. Lu C, Wang Y, Xu T, et al. Genistein ameliorates scopolamine-induced amnesia in mice through the regulation of the cholinergic neurotransmission, antioxidant system and the ERK/CREB/BDNF signaling. Front Pharmacol. 2018;9(OCT):1-11. doi:10.3389/fphar.2018.01153
  9. Chen BH, Park JH, Lee TK, et al. Melatonin attenuates scopolamine-induced cognitive impairment via protecting against demyelination through BDNF-TrkB signaling in the mouse dentate gyrus. Chem Biol Interact. 2018;285(January):8-13. doi:10.1016/j.cbi.2018.02.023
  10. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 2003;28(4):694-703. doi:10.1038/sj.npp.1300091
  11. Rainer Q, Xia L, Guilloux JP, et al. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol. 2012;15(3):321-335. doi:10.1017/S1461145711000356
  12. Can ÖD, Üçel Uİ, Özkay ÜD, Ulupınar E. The effect of agomelatine treatment on diabetes-induced cognitive impairments in rats: Concomitant alterations in the hippocampal neuron numbers. Int J Mol Sci. Published online 2018. doi:10.3390/ijms19082461
  13. Molteni R, Calabrese F, Pisoni S, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry. 2010;11(2):148-153. doi:10.3109/15622970903447659
  14. Gumuslu E, Mutlu O, Sunnetci D, et al. The antidepressant agomelatine improves memory deterioration and upregulates CREB and BDNF gene expression levels in unpredictable chronic mild stress (UCMS)-exposed mice. Drug Target Insights. 2014;2014(8):11-21. doi:10.4137/DTI.S13870
  15. Martin V, Allaïli N, Euvrard M, et al. Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice. Sci Rep. 2017;8(March):1-11. doi:10.1038/srep45907
  16. Gupta S, Singh P, Sharma B, Sharma B. Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia. Curr Neurovasc Res. 2015;12(3):240-252. doi:10.2174/1567202612666150603130235
  17. Özkay ÜD, Söztutar E, Can ÖD, Üçel UI, Öztürk Y, Ulupinar E. Effects of long-term agomelatine treatment on the cognitive performance and hippocampal plasticity of adult rats. Behav Pharmacol. Published online 2015. doi:10.1097/FBP.0000000000000153
  18. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. Published online 1988. doi:10.1016/0166-4328(88)90157-X
  19. Tian SW, Xu F, Gui SJ. Apelin-13 reverses memory impairment and depression-like behavior in chronic social defeat stressed rats. Peptides. Published online 2018. doi:10.1016/j.peptides.2018.08.009
  20. Saral S, Topçu A, Alkanat M, et al. Apelin-13 activates the hippocampal BDNF/TrkB signaling pathway and suppresses neuroinflammation in male rats with cisplatin-induced cognitive dysfunction. Behav Brain Res. 2021;408:113290. doi:10.1016/j.bbr.2021.113290
  21. Jafarian S, Ling KH, Hassan Z, Perimal-Lewis L, Sulaiman MR, Perimal EK. Effect of zerumbone on scopolamine-induced memory impairment and anxiety-like behaviours in rats. Alzheimer’s Dement Transl Res Clin Interv. 2019;5:637-643. doi:10.1016/j.trci.2019.09.009
  22. Janas AM, Cunningham SC, Duffy KB, et al. The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. Life Sci. 2005;76(10):1073-1081. doi:10.1016/j.lfs.2004.06.028
  23. Lee JC, Park JH, Ahn JH, et al. Effects of chronic scopolamine treatment on cognitive impairment and neurofilament expression in the mouse hippocampus. Mol Med Rep. 2018;17(1):1625-1632. doi:10.3892/mmr.2017.8082
  24. Kim DH, Ryu JH. Differential effects of scopolamine on memory processes in the object recognition test and the Morris water maze test in mice. Biomol Ther. 2008;16(3):173-178. doi:10.4062/biomolther.2008.16.3.173
  25. Ko YH, Kwon SH, Lee SY, Jang CG. Isoorientin improves scopolamine-induced cognitive impairments by restoring the cholinergic system, antioxidant defense, and p-CREB/BDNF signaling in the hippocampus and frontal cortex. Arch Pharm Res. 2019;42(8):722-731. doi:10.1007/s12272-019-01172-7
  26. Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci. 2018;210(August):177-184. doi:10.1016/j.lfs.2018.09.003
  27. Lee B, Shim I, Lee H, Hahm DH. Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats. J Microbiol Biotechnol. 2011;21(8):874-883. doi:10.4014/jmb.1104.04012
  28. Klaassens BL, van Gerven JMA, Klaassen ES, van der Grond J, Rombouts SARB. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer’s disease. Neuroimage. 2019;199(October 2018):143-152. doi:10.1016/j.neuroimage.2019.05.044
  29. Wong-Guerra M, Jiménez-Martin J, Fonseca-Fonseca LA, et al. JM-20 protects memory acquisition and consolidation on scopolamine model of cognitive impairment. Neurol Res. 2019;41(5):385-398. doi:10.1080/01616412.2019.1573285